News

Mark Egerton, CEO of Quotient Sciences has been featured in and article in Global Business Reports: A Shifting Landscape; The outsourcing model is here to stay

Mark Egerton, CEO of Quotient Sciences has been featured in and article in Global Business Reports: A Shifting Landscape The outsourcing model is here to stay

In addition to speed, clients also want ease. Rather than working with several service providers along a product’s lifecycle, for example, it is much easier to work with just a few. To streamline the drug development process, Quotient Sciences’ CEO Mark Egerton sees value in CDMOs managing both drug substance and drug product in parallel. “Previously, customers would use service providers upstream from us and make decisions on which compounds to progress without much consideration of what would happen downstream,” explained Egerton. “The customer would sometimes manufacture the drug substance only to find out later they had made an error in the compound selection process. Having already made significant investment, they are reluctant to take a step back and thus start to make compromises for their downstream development plan.”

Read the full article